Skip to main content

Genesis Protect availability

Start here if

Use this page before describing, selling, integrating, or reviewing Genesis Protect Acute.

Current public boundary

Genesis Protect Acute is on a bounded mainnet launch target.

It is not broadly available insurance today.

What is true now

  • Travel 30 is the primary launch SKU.
  • Event 7 is the fast demo SKU.
  • Product terms, evidence requirements, and reserve-lane wording are published.
  • Phase 0 claim review is operator-backed.
  • Protection issuance depends on posted reserve, staffed review operations, and published metadata staying aligned.

What this page does not claim

  • It does not claim broad always-on public issuance today.
  • It does not claim fully decentralized claim review today.
  • It does not claim that app membership fees are claims-paying reserve.
  • It does not claim that unposted demand, future yield, or narrative momentum count as reserve.
  • It does not claim that a product can stay open after reserve, staffing, schema, pricing, or benefit truth drifts from the published launch posture.

Issuance gates

GateTravel 30Event 7
Posted reserveTravel 30 premium and liquidity lanes must support the marketed issuance window.Event 7 premium, sponsor, or liquidity support must cover the approved cohort or issuance window.
Review staffingOperator-backed claim review must be staffed for the active issuance window.Operator-backed claim review must be staffed for the active issuance window.
Public termsPublished pricing, benefit, exclusion, and evidence truth must stay aligned.Published pricing, benefit, exclusion, sponsor, and evidence truth must stay aligned.
Metadata/schemaShared public evidence schema and launch metadata must remain consistent.Shared public evidence schema and launch metadata must remain consistent.

Pause conditions

Issuance should pause when:

  • posted reserve no longer covers the marketed issuance window
  • claims operator or oracle staffing falls below required Phase 0 review readiness
  • published schema, pricing, benefit, or evidence truth drifts from launch metadata
  • sponsor-backed issuance is described without explicit sponsor or backstop support
  • marketing language starts implying broad insurance availability instead of bounded launch availability

Reader checklist

ReaderCheck before proceeding
MemberThe protection window is active, the SKU fits the event, and the evidence expectations are clear.
SponsorThe cohort lane, reserve source, review readiness, and published terms are explicit.
BuilderPublic SDK work stays devnet-first unless OmegaX announces mainnet availability.
OperatorProduct availability, reserve truth, and staffing readiness are aligned before issuance stays open.

Next read